8.56
전일 마감가:
$8.22
열려 있는:
$8.57
하루 거래량:
7,353
Relative Volume:
0.01
시가총액:
$327.40M
수익:
$127.70M
순이익/손실:
$-121.25M
주가수익비율:
-2.7175
EPS:
-3.15
순현금흐름:
$-120.32M
1주 성능:
+9.03%
1개월 성능:
+16.64%
6개월 성능:
+4.45%
1년 성능:
-51.34%
아이테오스 Stock (ITOS) Company Profile
명칭
Iteos Therapeutics Inc
전화
857-204-4583
주소
321 ARSENAL STREET, WATERTOWN
ITOS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ITOS
Iteos Therapeutics Inc
|
8.555 | 305.04M | 127.70M | -121.25M | -120.32M | -3.15 |
![]()
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
아이테오스 Stock (ITOS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2025-05-14 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
2025-05-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2024-08-13 | 개시 | Wells Fargo | Overweight |
2021-05-05 | 개시 | H.C. Wainwright | Buy |
2020-10-08 | 개시 | Robert W. Baird | Outperform |
2020-08-18 | 개시 | JP Morgan | Overweight |
2020-08-18 | 개시 | Piper Sandler | Overweight |
2020-08-18 | 개시 | SVB Leerink | Outperform |
2020-08-18 | 개시 | Wedbush | Outperform |
모두보기
아이테오스 주식(ITOS)의 최신 뉴스
Balyasny Asset Management L.P. Buys Shares of 28,350 iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Q2 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World
Q4 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World
The week in pharma: action, reaction and insight – week to May 16 - The Pharma Letter
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet - MSN
Research Analysts Issue Forecasts for ITOS Q2 Earnings - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $18.83 Average Target Price from Analysts - Defense World
iTeos Therapeutics (NASDAQ:ITOS) Rating Lowered to “Hold” at Leerink Partnrs - Defense World
Leerink Partners Reiterates “Market Perform” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
ITOS: ITeos Therapeutics Downgraded to Neutral by HC Wainwright & Co. | ITOS Stock News - GuruFocus
iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating (NASDAQ:ITOS) - Seeking Alpha
Piper Sandler cuts iTeos stock price target to $12 from $16 - Investing.com Canada
ITeos Therapeutics (ITOS) Sees Price Target Adjustment by Piper Sandler | ITOS Stock News - GuruFocus
iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish - NewsBreak: Local News & Alerts
ITeos Therapeutics (ITOS): Analyst Lowers Price Target, Rating R - GuruFocus
Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth - TipRanks
ITeos Therapeutics (ITOS) Downgraded by Leerink Partners | ITOS Stock News - GuruFocus
This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday - Benzinga
Leerink Downgrades iTeos Therapeutics to Market Perform From Outperform - marketscreener.com
HC Wainwright Downgrades iTeos Therapeutics to Neutral From Buy - marketscreener.com
iTeos Therapeutics (ITOS) Receives Adjusted Price Target from We - GuruFocus
iTeos Therapeutics (ITOS) Receives Adjusted Price Target from Wells Fargo | ITOS Stock News - GuruFocus
iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decisi - GuruFocus
GSK (GSK) and iTeos Halt Belrestotug Development After Disappoin - GuruFocus
iTeos Therapeutics price target lowered to $12 from $16 at Piper Sandler - TipRanks
iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decision | ITOS Stock News - GuruFocus
GSK (GSK) and iTeos Halt Belrestotug Development After Disappointing Trial Results | GSK Stock News - GuruFocus
iTeos Therapeutics (ITOS) Downgraded by Analyst with New Price T - GuruFocus
Leerink downgrades iTeos Therapeutics after termination of TIGIT program - TipRanks
iTeos and GSK halt lung cancer drug development By Investing.com - Investing.com India
GSK, partner iTeos end development programme for lung cancer drug belrestotug - Medical Dialogues
ITeos Therapeutics (ITOS) Downgraded by JP Morgan | ITOS Stock N - GuruFocus
As iTeos, GSK shelve belrestotug, prospects for TIGIT continue to dim - BioCentury
iTeos Therapeutics: TIGIT Falls, And A Zombie Rises? (NASDAQ:ITOS) - Seeking Alpha
iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop - insights.citeline.com
JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 - Investing.com Australia
GSK and iTeos end belrestotug antibody program By Investing.com - Investing.com Nigeria
JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 By Investing.com - Investing.com Nigeria
iTeos Therapeutics (ITOS) Downgraded by JPMorgan Analyst | ITOS Stock News - GuruFocus
GSK, partner iTeos scrap development of lung cancer therapy - NewsBreak: Local News & Alerts
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile - Yahoo Finance
iTeos and GSK to drop belrestotug + dostarlimab collaboration - The Pharma Letter
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Stu - GuruFocus
iTeos, GSK to shelve TIGIT drug after study setback - BioPharma Dive
ITeos Terminates TIGIT Program After Phase 2 Lung Study Misses PFS Endpoint, Explores Options - Nasdaq
ITeos, GSK discontinue lung cancer therapy development - KFGO
Wedbush Adjusts Price Target on iTeos Therapeutics to $10 From $25, Maintains Outperform Rating - marketscreener.com
GSK (GSK) and iTeos Halt Development of Lung Cancer Drug Combo - GuruFocus
GSK, iTeos Therapeutics End Belrestotug Development Program - marketscreener.com
iTeos stock rises despite clinical trial setback By Investing.com - Investing.com South Africa
iTeos stock rises despite clinical trial setback - Investing.com Australia
아이테오스 (ITOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):